Early, Accurate, and Non-Invasive Detection of Staphylococcus Aureus Infections.
Sabiad is a medical technology company specializing in early, non-invasive detection of bacterial infections, focusing on Staphylococcus aureus. Our technology, StaphMark, offers real-time imaging for orthopedic and trauma surgeries without radiation exposure, reducing costs and complications, and improving patient outcomes.
Current detection technologies do not accurately distinguish inflammation from infection.
Patient infected by SA after a TJA are not diagnosed early enough to avoid medical complications.
More than 1.5 million TJA procedures are performed in US and Europe every year. >2,5% of these patients get infected by SA.
The main factors driving the need for Total Joint Arthroplasty (hip & knee) are aging population, overweight / obesity and mechanical stress. Therefore the number of TJAs is expected to significantly increase in the future
Mitigate Antimicrobial Resistance (AMR) by avoiding unnecessary antibiotics. Protect patient health and reduce healthcare costs.
Improve diagnostic accuracy, leading to earlier treatment and better patient outcomes.
Achieve precise differentiation between infections and inflammation, aiding in targeted care.
Enable patient-centric care with immediate infection confirmation for informed decision-making.
Cut costs significantly through early interventions and precise diagnoses, benefiting patients and healthcare providers.
Enhance patient recovery and comfort while minimizing complications, supporting better overall care.